UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/578,706	05/10/2006	Vitali Tararov	LNK-014	3660
31496 7590 01/18/2008 SMITH PATENT CONSULTING CONSULTING, LLC 3309 DUKE STREET			EXAMINER	
			DENTZ, BERNARD I	
ALEXANDRIA, VA 22314		ART UNIT	PAPER NUMBER	
			1625	
			MAIL DATE	DELIVERY MODE
			01/18/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/578,706	TARAROV ET AL.			
Office Action Summary	Examiner	Art Unit			
	Bernard Dentz	1625			
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address			
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	 I. nely filed the mailing date of this communication. D (35 U.S.C. § 133). 			
Status					
Responsive to communication(s) filed on 12-26 This action is FINAL . 2b) ☑ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ⊠ Claim(s) 1-15 is/are pending in the application. 4a) Of the above claim(s) See Continuation She 5) □ Claim(s) is/are allowed. 6) ☒ Claim(s) 1-4,6-10,12 and 15 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	<u>eet</u> is/are withdrawn from conside	eration.			
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate			

Continuation of Disposition of Claims: Claims withdrawn from consideration are 5 and 11,13 and 14 and non-elected parts of claims 4,6-10 and 12.

Application/Control Number:

10/578,706 Art Unit: 1625

The restriction is proper because the US Patent 5,286,883 discloses that the product of the reduction is commonly converted into the corresponding lactone. See col. 1,lines 14-32. It is made final. Non-elected claims 5, 11, 13 and 14 are withdrawn from consideration.

Claims 1-3 and 15 in whole and claims 4, 6-10 and 12 in part, are deemed to read on the elected process. Applicants have elected a multi-step process for making atorvastatin in which a key intermediate is compound (I) in which R is CH2CH2NH2 recited in part (e) of claim 4.

This compound is made by reducing the corresponding CH2CH2CN (the cyanoethyl) compound.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-4,6-10, 12 and 15 are rejected under 35 USC 101 since the disclosed invention is inoperative and therefore lacks utility. The multi-step synthesis is based on steps which have been disclosed as inoperative in a journal article of which all 3 of the instant inventors are authors.

The process of part (e) of claim 4 requires the conversion of a compound of formula (I) where R is CH_2R^2 where R^2 is tosylate into the compound where R^2 is cyano. See p. 12, lines 14-16 and p. 25, line 10.

However Tararov et al. Eur. J. Org. Chem, P. 5543-5550 (2006) discloses that preferred compounds of instant formula (I) (see p. 8 of the specification) in which instant

Application/Control Number:

10/578,706 Art Unit: 1625

S¹ is tert-butyldiphenylsilyl or tert-butyldimethylsilyl and R² is tosylate or iodo could not be converted to the corresponding cyano compound

See p.5545, col. 2, second complete par. in which the first sentence is: "Unfortunately, it was not possible to achieve substitution of the tosyl group by cyanide under a variety of conditions." See the rest of the par. where a wide variety of conditions are described.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4,6-10, 12 and 15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Of course claims 1-3, 6-10 and 15 are incomplete in not (especially independent claim 1) in not reciting the elected process for making atorvastatin given in claim 4 part (e). Applicants must draw claim 1 to the elected method for making atorvastatin.

Applicants must cancel all of the non-elected material from the claims

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon.-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number:

10/578,706

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz

1-11-2008

BERNARD DENTZ PRIMARY EXAMINER